Medtronic (MDT) passes a quality dividend screen with a 7/10 rating, 3.35% yield, strong profitability, and a sustainable payout—though health and payout ratio merit caution.

According to the average brokerage recommendation (ABR), one should invest in Medtronic (MDT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Medtronic stock has delivered a 20.8% gain over the past three years, yet current checks suggest it now sits close to its estimated intrinsic value rather than at a clear discount. At the same time, earnings-based multiples still screen the shares as undervalued, which sets up a debate over how much upside is left from here. A 20.8% return over three years points to steady value creation for Medtronic shareholders, not a rapid rerating. Progress in higher-margin cardiovascular devices,...